[______________ FORM 8-K ______________ CURRENT REPORT Date of Report (Date of earliest event reported): May 1, 2013 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨]

[______________ FORM 8-K ______________ CURRENT REPORTte of Report (Date of earliest event reported):May 1, 2013 BIOSTAR PHARMACEUTICALS, Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer oforporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province Peoples Republic of China 712046 86-029-33686638 N/A (Former name or formerdress, if changed since last report)]

[Biostar Pharmaceuticals, Inc. Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results for the full year ended December 31, 2012. SUMMARY FINANCIALS Full Year 2012]

[Biostar Pharmaceuticals, Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced financial results for the full year ended December 31, 2012.]

[FORM 10-K (Mark One) x December 31, 2012 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Product Research and Development Agreement Party A: Shaanxi Aoxing Pharmaceutical Co. Ltd. Party B: Life Science Academy of Northwest University Party A and Party B reached the following R&D agreement regarding National Type I new medicine Danshensu Borneol Ester through friendly negotiation: 2. Project research progress: (1) Party B has finished the research of DBZ’s activity, technical, quality standard and] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (No. 333-161598) and S-8 (No. 333-183387) of Biostar Pharmaceuticals, Inc. of our report dated April 11, 2013 relating to the consolidated financial statements, which appears in the Annual Report] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Mazars CPA Limited Certified Public Accountants Hong Kong April 11, 2013 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2013 Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 8 ex32-2.htm]